CMS ACCESS Model and New York Healthcare

I would translate the model into a chain of enforceable obligations before building the commercial offer. Which organization is responsible for clinical delivery? Who identifies eligible patients and confirms that the pathway is appropriate? What information must follow the referral? Which evidence permits payment, and who carries the cost while that evidence accumulates? Those questions determine whether the opportunity is a software sale, a care-delivery business or a partnership with distinct responsibilities.

For a New York strategy, geography should define an actual service network rather than a market-size claim. A dense provider map does not establish usable access: payer participation, specialty availability, language, referral processes and the patient’s preferences can make nearby services functionally separate. I would select a bounded referral corridor where the organizations can test those interfaces and maintain responsibility when a handoff fails.

The initial partner should be chosen for implementation authority as well as patient volume. A large institution may offer reach while requiring several independent budget and clinical approvals. A narrower partner may make the complete pathway testable sooner. Compare those options by time to a functioning service, funded capacity and the evidence each can produce. The largest logo is not automatically the best first investment.

Keep Medicare payment assumptions separate from Medicaid, employer and community-health propositions. An intervention may serve similar clinical needs across those populations while operating under different coverage, purchasing and accountability arrangements. I would carry a separate contract and contribution model for each route. Blending them can make an attractive population-health narrative conceal an unfunded delivery obligation.

For the selected corridor, build a cohort ledger from referral through collection. Include screening and outreach that do not convert, work performed by the referring practice, clinical delivery, measurement and administrative exceptions. Model the cash required during the ramp and compare it with the amount the organization can commit. A clinically appropriate pathway can still require a subsidy or a different commercial structure; that conclusion should be visible before expansion.

I would expand only when the pilot answers three unresolved questions: whether eligible patients complete the intended care, whether partners can deliver it within their actual capacity and whether the payment arrangement covers the full incremental obligation. If referrals are strong but completion fails, repair the receiving service. If care is delivered but the evidence cannot support collection, repair measurement and contracting. Additional sales capacity should follow the bottleneck that the pilot identifies.